Shares of clinical contract research organization Medpace Holdings, Inc. (MEDP) are down more than 10% Tuesday morning at $132.7 despite first-quarter earnings topping estimates.
Monday, the company reported net income of $61.3 million, or $1.69 per share in the first quarter, compared with $43.3 million, or $1.14 per share in the same quarter a year ago. The consensus estimate of analysts polled by Thomson Reuters was for $1.26 per share.
Revenue for the quarter increased 27.3% year-on-year to $330.95 million.
Looking forward, Medpace forecasts 2022 revenue in the range of $1.400 billion to $1.460 billion and earnings per share to be in the range of $5.72 to $6.06.
Analysts expect earnings of $5.61 per share on revenue of $1.41 billion for the period.
MEDP has traded in the range of $132.46-$231 in the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.